Patents | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1333 of 1777  at  10/29/2018 8:22:42 AM  by

warlord_2010


 In response to msg 1331 by  peterahoward
view thread

Re: Patents

This was published one week after Heplisav was approved: 

Asked during the conference call about an ongoing intellectual property dispute regarding Heplisav-B, Michael Ostrach, chief business officer, said he does not "expect the patents controlled by GSK and Merck will prevent us from marketing Heplisav-B, and although we don't discuss details of ongoing discussions, I think it's fair to say that all three companies would agree that the best outcome for all of us will be license agreements containing reasonable royalty terms or the equivalent. You'll recall that the GSK-controlled patents expire in June or about a quarter after our launch."

 

Kenilworth, N.J.-based Merck & Co. Inc.'s patent "expires about two and a half years after launch, [but] Merck's out of the market, based on their announcement, for all of next year," he said. Merck has said worldwide demand caused a shortage of its Recombivax-HB.
 
http://www.bioworld.com/content/savoring-acip-victory-dynavax-looks-ahead-heplisav-b-price-come-0


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 265
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1334 Re: Patents fairvalueforyou 5 10/29/2018 8:40:40 AM
1335 Re: Patents peterahoward 2 10/29/2018 1:11:18 PM






Financial Market Data provided by
.


Loading...